NCT06630221 2025-07-03
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Case Comprehensive Cancer Center
Phase 2 Recruiting
Clinical Trials
5 trialsNCT01957176 2022-12-30
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Phase 4 Completed
NCT01893372 2020-02-18
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01440374 2017-06-05
ASPIRE
Novartis
Phase 2 Completed
NCT01488565 2016-02-15
Aza-E
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed